DURAVYU - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Representative image of SAP headquarters in Walldorf, Germany, as the European Commission investigates ERP maintenance policies

SAP (NYSE: SAP) bets €1bn on Prior Labs and Dremio as enterprise AI strategy widens

Adani Ports breaks out at record Rs 1,747 as 500 MMT milestone meets Hormuz reroute trade (NSE: ADANIPORTS)

Newark landing scare: United Airlines jet strikes bakery truck before safe touchdown

Why ASX retail investors are watching Energy Resources of Australia (ASX: ERA) collapse to the Rio Tinto buyout floor

EyePoint Pharmaceuticals shares interim Phase 2 PAVIA trial results for DURAVYU, revealing promising safety but missing primary endpoints in NPDR treatment.

Read More

Pharma Industry News

EyePoint Pharmaceuticals reports mixed results for DURAVYU in Phase 2 diabetic retinopathy trial

EyePoint Pharmaceuticals, Inc., committed to innovative therapeutics for serious retinal diseases, today disclosed the top-line results of the…

byPallavi Madhiraju

May 7, 2024

web analytics